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Endovascular treatment of celiac and mesenteric
arteries stenoses: Applications and results
Melhem J. Sharafuddin, MD,a,b Craig H. Olson, BS,a Shiliang Sun, MD,b Timothy F. Kresowik, MD,
FACS,a and John D. Corson, MB, ChB, FRCS(Eng), FRCS(Ed), FACS,a Iowa City, Iowa
Purpose: To evaluate the safety and assess the role of endovascular therapy in a variety of conditions related to celiac and
mesenteric vascular occlusive disease.
Patients and methods: Our retrospective study population included 25 consecutive patients (mean age, 66 years), in whom
28 procedures were performed on 26 stenosed or occluded mesenteric vessels (superior mesenteric artery [SMA] or celiac
artery [CA]). Indications included chronic mesenteric ischemia (21 patients), including 2 patients who underwent
stenting prior to a planned operative repair of a juxtamesenteric AAA. Three liver transplantation patients underwent
stenting of an associated CA stenosis. One patient with a splenorenal bypass underwent stenting on an associated CA
stenosis. The technical and clinical success rates and the incidence of complications were determined. Follow-up
parameters included maintained patency on duplex sonography and sustained clinical benefit. The need for additional
interventions was noted.
Results: All procedures but one were technically successful (96%). Major complications occurred in three patients (one
transient contrast-induced nephrotoxicity and two pseudoaneurysms). Immediate clinical success was achieved in 22
patients (88%). The three clinical failures included two patients with an excellent angiographic outcome, but with
single-vessel moderate severity disease. Survival table analysis of delayed clinical outcome showed primary and primary-
assisted clinical benefits at 11 months of 85% and 91%, respectively. Primary and primary-assisted stent patencies, as
assessed by duplex sonography and/or angiography, at 6 months were both 92%. Angiographically documented
restenosis occurred in three patients. Restenosis in two patients with CA stents was due to extrinsic compression, and it
was without symptoms in one patient and was treated satisfactorily by restenting in the other patient. Restenosis in one
patient with an SMA stent was successfully treated by restenting.
Conclusions: Our experience suggests a potential role for endovascular therapy of celiac and mesenteric arterial occlusive
disease in a variety of clinical scenarios, with a low incidence of complications and a high technical success rate. (J Vasc
Surg 2003;38:692-8.)
Balloon angioplasty and/or stenting has become an
established treatment modality for arterial occlusive dis-
eases in a variety of peripheral vascular beds.1 However, the
use of endovascular therapy in the mesenteric vasculature
has not been as widely accepted. Results from earlier series
reporting on the use of endovascular techniques in the
management of mesenteric occlusive disease have indicated
reasonable rates for technical success (79% to 100%) and
short-term efficacy (63% to 100%), although most have
indicated disappointing long-term efficacy (52% to 80%)
when compared with open surgical reconstruction.2-15
However, these endovascular data generally reflect early
experiences, which may have been compromised by early
generation devices and delivery systems. Moreover, most
published series of endovascular mesenteric revasculariza-
tion include a large proportion of balloon angioplasty pro-
cedures done alone without stenting. If one was to draw an
analogy with the renovascular bed, where more recent
literature suggests increasingly favorable technical success
and improved long-term patency rates with the use of
newer-generation stent technology,16 it is reasonable to
project a similar trend in outcomes of endovascular therapy
in the mesenteric circulation beds.17,18 The purpose of this
study was to evaluate our current experience with endovas-
cular stenting in the celiac and superior mesenteric arteries,
using modern stent technology and delivery systems, to
determine the safety and assess the role of endovascular
therapy in a variety of conditions related to celiac and
mesenteric vascular occlusive disease.
PATIENTS AND METHODS
Our study was a retrospective review of all patients in
our institution who underwent attempted stent-assisted
angioplasty of a mesenteric vessel from July 1999 through
June 2002. Two patients who underwent balloon angio-
plasty alone without stenting were excluded. Twenty-five
consecutive patients were identified (13 men and 12 wom-
en), in whom 28 procedures were performed on 26 indi-
vidual vessels. This included two secondary interventions to
treat one patient with restenosis and one patient who had
prior unsuccessful stenting. The most frequent indication
for intervention was chronic mesenteric ischemia, present-
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ing in 21 of our patients. Sixteen patients presented with
abdominal angina, and five patients presented with lower
gastrointestinal bleeding secondary to ischemic colitis. To
simplify the operative approach, stenting of the superior
mesenteric artery (SMA) and/or celiac artery (CA) was
undertaken prior to elective operative repair of a juxtasupe-
rior mesenteric artery abdominal aortic aneurysm (AAA) in
two patients, who also had a history of postprandial abdom-
inal pain. Three liver transplantation patients also under-
went stenting of a celiac artery (CA) stenosis. One patient,
with a patent splenorenal bypass graft, underwent stenting
of a stenosed CA for control of recurrent hypertension. An
endovascular approach was selected in these patients for a
variety of reasons, including high risk for open surgery,
reluctance to reoperate due to recent abdominal surgery,
surgeon preference, or patient preference when the patient
specifically requested an endovascular procedure when pre-
sented with the various options. Of note, during the same
time period of the study, the two staff surgeons participat-
ing in the study (J.D.C., T.F.K) performed a total of eight
open mesenteric revascularization procedures, of which six
were elective aortomesenteric bypasses for chronic mesen-
teric ischemia and two were acute procedures in patients
with acute mesenteric ischemia. The general demographic
data, prevalence of vascular risk factors, and follow-up are
listed in Table I.
The angiographic characteristics and distribution of the
occlusive disease as well as the performed endovascular
interventions are summarized in Table II. Eighteen pa-
tients had pre-procedure magnetic resonance angiograms
(MRAs) or computerized tomographic angiograms
(CTAs). Seventeen patients had a preprocedure ultrasound
scanning examination with Duplex evaluation of the SMA
and CA. Prior diagnostic conventional angiograms were
available in only five patients, with the remaining patients
undergoing the angiographic procedure with the intent to
treat on the basis of a prior abnormal US or MRA/CTA
studies.
Stent-assisted angioplasty was used in all patients. All
procedures were performed percutaneously. A femoral ap-
proach was used for 21 procedures (75%), whereas a bra-
chial approach (either primary or adjunctive) was used for 7
procedures. A preintervention aortogram was obtained in
the lateral projections. An aortogram in the anteroposterior
(AP) projection and selective angiogram of the SMA or CA
vessels were then obtained on a selective basis. After tra-
versal of the lesion with an appropriate catheter-guide wire
combination, the lesion was predilated with a 3- to 4-mm-
diameter low-profile angioplasty balloon, after which the
stent was deployed in a standard manner. Postdilation to an
appropriate diameter was routinely performed by using
high-pressure inflation. A variety of both balloon-expand-
able and self-expanding stents were used (Table II). When
ostial lesions were treated, care was taken to cover the
ostium while avoiding more than 2-mm maximal prolapse
of the stent into the aortic lumen. A completion angiogram
was performed in the lateral projection, with selective an-
giography of the stented vascular bed. After removal of the
hardware, hemostasis was achieved by manual compression
in 16 procedures or by the use of a vascular closure device in
the remaining procedures. All patients received 3000 to
7000 IU of heparin intraprocedurally. All patients were
maintained on aspirin (81 or 325 mg daily) and clopidogrel
(75 mg daily). The patients were followed up at various
time intervals (usually 1 month, 3 months, 6 months, and
then annually) both clinically and by duplex sonography.
Technical success was defined as a postintervention
residual stenosis of30%. Clinical outcomes were qualified
as either good or poor, depending on the underlying
disease process as follows: (1) abdominal angina: resolution
or improvement of symptoms and weight gain; (2) liver
transplantation: reversal of enzymatic and/or Doppler he-
Table I. Demographics and clinical presentation of the patients
Age (y) M/F Vascular risk factors
Intervention
indications
Duplex
follow-up
(mo)
Angiographic
follow-up
(mo)
Clinical
follow-up
(mo)
66.9  10.9
range: 41–86
(n  25)
M: 13 DM: 5/25 -Mesenteric angina: 15 Range: 1–32 Range: 3–31 Range: 1–35
F: 12 Smoking: 15/25 -gastric angina: 1 Median: 9.5 Median: 14 Median: 11.5
HTN: 18/25 -Ischemic colitis: 5 Mean: 14.0 Mean: 18.6 Mean: 15.0
Hyperlipidemia: 16/25 -Pre-AAA surgery: 2* SD: 14.7
(n  18)
SD: 17.4
(n  7)
SD: 14.7
(n  24
‡
)CRI: 6/25 -Liver transplant
dysfunction: 3
-Renal dysfunction,
s/p splenorenal
bypass: 1
-Stent restenosis
†
: 2
DM, Diabetes mellitus; HTN, hypertension; CR, chronic renal insufficiency.
*Both patients also had suspected symptomatic mesenteric occlusive disease and although the procedure was performed primarily simplify the operative
management of juxta-renal AAA.
†
One liver transplant patient developed immediate CA stent restenosis. The other patient developed delayed SMA stent restenosis presenting with recurrent
abdominal angina.
‡
Excludes one patient who died 11 days postprocedure.
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modynamic abnormality; and (3) insufficient splenorenal
bypass: control of hypertension. Clinical follow-up in-
cluded assessment of the patient abdominal symptoms and
weight. Duplex sonography follow-up consisted of color-
flow and duplex examination of the CA and SMA. On
delayed follow-up, sustained primary clinical benefit refers
to a favorable clinical outcome without the need of further
intervention, whereas sustained primary-assisted clinical
benefit refers to the requirement of re-intervention(s) to
maintain or restore clinical benefit. All outcomes were
analyzed on an intent-to-treat basis.
Statistical comparison of the various variables was per-
formed using SYSTAT 8.0 software (SPSS Inc, Chicago,
Ill). Continuous numeric variables were compared by using
the Student t test, whereas discrete numeric variables were
compared by using the Mann–Whitney nonparametric test.
The Pearson 2 probability test was used for comparing
non-numeric categorical variables. Life-table analysis was
performed by using GraphPad Prism software (Graph Pad
Software, San Diego, Calif).
RESULTS
Technical success was achieved in all but one procedure
(96%). The failed procedure occurred in a patient who
presented with liver transplant malfunction. Angiography
revealed a tight stenosis of the CA causing ischemia of the
allograft. During the initial stenting procedure, there was a
poor response after using a single balloon-expandable
Corinthian stent. The almost immediate and nearly com-
plete recoil of the lesion was thought to be due to extrinsic
compression by the median arcuate ligament. The patient,
who did not desire operative intervention, later underwent
a second endovascular procedure with placement of an
oversized Nitinol stent through the prior collapsed stent.
Although a moderate residual stenosis persisted, the lumen
was adequate to allow sustained improvement in the liver
function tests and normalization of duplex ultrasound scan-
ning parameters.
The immediate clinical outcome after intervention was
classified as good in 22 patients (88%) and poor in 3
patients, including 2 who had a technically excellent angio-
graphic outcome. Interestingly, both of the latter two
patients had only moderate stenosis of the affected artery
(SMA in one and CA in the other) and essentially a single
vessel disease distribution, but underwent endovascular
therapy nonetheless as a therapeutic trial after other patho-
ses had been excluded. One of these two patients who failed
to improve with stenting went on to have a surgical bypass
without improvement in her symptoms, and the other was
eventually felt to have poor gastric emptying as a cause for
his symptoms and underwent placement of a gastric pace-
maker with some improvement. The liver transplant pa-
tient, who had an initial technically unsuccessful procedure,
has already been mentioned.
Late clinical outcome (mean/median follow-up:
15/12 months) showed sustained primary clinical benefit
in 20 patients (83%). Sustained primary-assisted clinical
benefit was achieved in 22 patients (92%) (Fig 1). This
included the one patient who had a suboptimal technical
outcome after the initial procedure but improved after
Table II. Angiographic characteristics of occlusive disease, and the performed interventions
Disease distribution Triple-vessel: 9
Double-vessel: 8 (CA  SMA: 3, SMA  IMA: 3, CA  IMA: 2)
Single-vessel: 8 (SMA: 4, CA: 4)
Treated vessels CA: 11
SMA: 18
One-vessel intervention: 27
Two-vessel intervention: 1
Lesion length (mm) 10.4  6.2
Stenosis severity (%) 81.6  12.9
Characteristics of treated lesions* Atherosclerosis: 23
Extrinsic ligamentous compression: 2
Extrinsic compression by tumor: 1
Ostial stenosis: 20/28
Complex stenosis
†
: 7
Complete occlusions: 3
Postintervention residual stenosis (%) 10.4  19.5
Stented segment length (mm) 20.5  9.3
Stent diameter (mm) 6.5  0.7 mm
Stent types and manufacturers Palmaz (Cordis; Miami, FL): 2
(P204M and P294; dilated to 6 mm)
Palmaz-Corinthian (Cordis; Miami, FL): 19
(PC154, PC204, and PC294; dilated to 5-7 mm)
SMART/Precise (Cordis; Miami, FL): 5
(20-40 mm lengths, 6-8 mm diameters)
Wallstent (Boston Scientific, Natick, MA): 2
(20 mm length, 6 mm diameter)
CA, Celiac artery; SMA, superior mesenteric artery; IMA, inferior mesenteric artery.
*There were 26 primary interventions and two secondary interventions in 25 patients.
†
Complex stenosis referred to long stenosis (20 mm long), heavily calcified or severely irregular lesions.
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re-intervention, and another patient who presented with
recurrent symptoms at 3 months after stenting of a proxi-
mal SMA stenosis and underwent successful restenting of a
high-grade restenosis, resulting in resolution of symptoms.
Both patients remained symptom-free and patent by duplex
parameters 7 and 3 months later, respectively. There were
no instances of symptomatic deterioration in any of the
remaining patients with initial symptomatic improvement,
on a mean follow-up of 15 months. This includes one
patient with an occluded gastroduodenal artery and CA
stenosis initially presenting with abdominal angina, who,
despite an angiographically documented 70% restenosis
due to uncovering of the stenotic lesion after distal dis-
lodgement of the self-expanding stent on a follow-up an-
giogram 2 years later, did not have recurrence of his initial
presenting symptoms.
Immediate post-procedural duplex ultrasound scan-
ning evaluation was available in 22 patients. In 17 patients,
both pre-intervention and post-intervention duplex studies
were available and showed improvement of the duplex
parameters in the treated vascular territory in 16 patients
(94%) and no improvement in 1 patient who had a techni-
cally unsuccessful procedure. Delayed duplex follow-up
data (mean/median follow-up: 14/9.5 months) was avail-
able in 18 patients, with stable to improved duplex param-
eters found in all (Table III). There was an excellent
correlation between a good clinical response and improve-
ment in the duplex parameters both post-procedurally and
on the late follow-up (Russell and Rao binary similarity
coefficient: 0.89 and 0.91, respectively). Long-term fol-
low-up of primary and primary-assisted patency by means
of duplex sonography and/or angiography is summarized
in Fig 2.
A restenosis developed after three procedures (one
immediate and two delayed). In one patient, as previously
noted, an immediate restenosis occurred during the proce-
dure due to elastic recoil of a balloon-expandable stent
placed across a CA stenosis. A delayed restenosis developed
after 2 of the remaining 27 successful procedures. One of
the two delayed restenoses developed in a balloon-expand-
able stent 3 months after the primary procedure. The
patient was symptomatic, prompting reintervention with
stent placement, which resulted in symptom alleviation and
normalization of Doppler parameters. In the other patient,
a restenosis occurred at least 18 months after placement of
a self-expanding stent across a CA stenosis. A prior angio-
gram had shown maintained patency, and the cause of
restenosis appeared to be forward dislodgement of the
stent, resulting in unmasking of the ostial CA stenosis.
However, forward flow was maintained with a celiac artery
PSV within the normal range, and the patient remained
asymptomatic. As a result, no intervention was performed.
There were three significant complications in a total of
28 (10%) procedures (Society of Interventional Radiology
Fig 1. Primary and primary-assisted symptom-free patency after SMA and CA stenting. Presented in life-table format.
Bars represent the standard error of the mean (SEM) values.
Table III. Changes in the angiographic and Doppler parameters of treated lesions
Preintervention
Immediate
postintervention P
Delayed
postintervention P
% stenosis (angiography) 81.6  12.9 (n  28) 10.4  19.5 (n  28) 0.0001 20  24.5 (n  7) NS
PSV (cm/sec) 379.7  84.6 (n  17) 227.3  115.6 (n  22) 0.0001 180.1  83.8 (n  18) 0.0001
RI
†
0.59  0.005 (n  4) 0.74  0.007 (n  3) 0.024 — —
Weight
‡
(Kg) 62.7  14.5 (n  14) — — 67.7  16.4 (n  14) 0.0002
P-values were generated by separate variance Student’s t test for numeric variables and Fisher-exact test for collateral filling. The significance cutoff was P 
0.05. Paired samples t tests were used to compare weights.
*Collateral filling data were pertinent in 24 procedures.
†
Refers only to the liver transplantation subpopulation.
‡
Refers only to the abdominal angina subpopulation.
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[SIR] class-C),19 which included one patient who devel-
oped acute renal failure requiring additional hospitalization
before resolution of the problem, and two patients with
pseudoaneurysms (femoral artery in one, brachial artery in
the other) who were managed by thrombin injection in one
and surgical repair in the other.
Five of the patients died in the follow-up period. One
death occurred 11 days postprocedure from pneumonia
and multisystem organ failure in a patient who had ad-
vanced intra-abdominal carcinoid tumor. That patient also
developed nonoliguric acute renal failure as a result of three
consecutive iodinated contrast studies, including the inter-
vention. His renal function was normalizing before dis-
charge. He presented locally 3 days later and shortly after
succumbed. The remaining four patients died at 12, 47, 76,
and 92 weeks post-procedure, all from cardiopulmonary
causes.
DISCUSSION
The technique of mesenteric percutaneous translumi-
nal angioplasty as an alternative to surgical revascularization
was first described in 1980.20 However, the use of endo-
vascular therapy in mesenteric vascular occlusive disease
artery stenting has been mostly limited to a few se-
ries.2,4,6,17,18 Recent studies have suggested an increasing
role for the endovascular management of occlusive mesen-
teric vascular disease.17,18 Our series is unique in that it
only included patients treated with modern stent technol-
ogy and delivery systems and followed for up to 35 months.
There was a high technical success rate, with the only
failure related to immediate stent recoil due to an extrinsic
compression. Favorable immediate clinical outcome oc-
curred in 88% of treated patients. There were three failures
attributable mostly to poor clinical and/or anatomic selec-
tion (moderate disease with other etiology for pain in two
patients, or CA stenosis due to compression by the median
arcuate ligament in one patient). Late clinical outcome at a
mean follow-up of 15 months showed sustained primary
clinical benefit in 83% of patients and sustained primary-
assisted clinical benefit in 92% of patients. Only two late
failures occurred in our series (3 and 18 months after the
initial procedure, respectively), with one being symptom-
atic and responding well to a secondary endovascular inter-
vention. There moderate-severity (SIR class-C)19 compli-
cations occurred (10%), with only one requiring surgical
intervention to repair a femoral pseudoaneurysm. There
were no instances of acute stent rethrombosis. There was
one post-procedure mortality occurring at 11 days from
pneumonia and multisystem organ failure in a patient with
advanced intra-abdominal malignancy.
The main Doppler parameter used to follow up the
patients postprocedurally was the PSV. A significant de-
crease in PSV occurred after successful stenting and was
sustained through the follow-up (Table III). Excellent
correlation was present between a favorable clinical re-
sponse and improvement in the duplex parameters, with an
improvement in duplex parameters noted in 94% of patients
immediately postprocedure. However, one should be
aware of the possibility of a persistent elevation of the PSV
after a technically and clinically successful procedure. This
was encountered in three patients in our series (pre-inter-
vention: 417  29 cm/sec, postintervention 362  37
cm/sec, P  .11). In all three, the completion angiograms
showed a widely patent stent with excellent forward flow in
the downstream vessels, and all experienced resolution of
their pre-procedure symptoms. In these instances, the PSV
was lower than the pre-intervention level, although it was
still considered in the abnormal range (275 cm/sec). In
such instances, the most helpful maneuver is to sample the
SMA beyond the stented area. Sustained high PSV along a
long segment of the SMA may indicate hyperdynamic flow
that can occur when a concomitant high-grade CA stenosis
or occlusion is present with competent gastroduodenal
collaterals. It is also important to perform these examina-
tions in a fasting state to avoid the effects of postprandial
hyperemia. By and large, the PSV is a sensitive follow-up
parameter to detect restenosis in both asymptomatic pa-
tients or patients presenting with recurrent symptoms.
Fig 2. Primary and primary-assisted anatomic patency after SMA and CA stenting, using duplex sonography and/or
angiography, presented in life-table format. Bars represent SEM values.
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In the subpopulation of patients presenting with
chronic mesenteric ischemia (21 patients), 9 patients had
three-vessel disease, 8 had two-vessel disease, and 4 had
one-vessel involvement of the SMA. Of those four patients,
three with severe SMA stenosis responded well to stenting,
whereas the remaining one (with only moderate SMA
stenosis) did not improve.
All three patients with severe single-vessel SMA stenosis
had complete and sustained resolution of their abdominal
angina symptoms after endovascular stenting. The observa-
tion that a high-grade single-vessel stenosis involving the
SMA may be significant and may represent an indication for
intervention has been also noted by others.17
Intervention on single vessel disease may also be indi-
cated in cases of liver transplantation with ischemic allograft
dysfunction due to CA stenosis. The same logic could apply
to renovascular ischemia in the presence of stenosis in the
inflow of a splanchnic-renal bypass graft, as illustrated in
another patient in our series.
In the presence of triple- or double-vessel disease,
including the SMA, we typically preferentially treated the
SMA. Alternatively, when SMA-CA disease is present with
a stenosed CA and occluded SMA, the CA was treated. This
approach resulted in a good clinical response in all but one
patient with multivessel disease who underwent single ves-
sel intervention. The exception was a patient with an oc-
cluded SMA and a moderate CA stenosis who underwent a
technically successful CA stenting with persistent symp-
toms. That patient later underwent an aortomesenteric
bypass with continued unabated symptoms now felt un-
likely to be due to vascular insufficiency. In our opinion,
given the favorable results achievable with a single vessel
intervention, performing an additional vessel intervention
could unnecessarily increase the risk of procedural compli-
cations.
Care must always be exerted before stenting a CA
stenosis because of the possibility of technical or early
clinical failures that can occur due to the presence of
extrinsic compression at the level of the median arcuate
ligament compression syndrome. These patients are typi-
cally younger, and the angiographic appearance of the
lesions is usually typical. Therefore, when this condition is
suspected, it is important to rule out dynamic compression
of the celiac artery by obtaining inspiration and expiration
lateral aortograms. Moreover, because of the risk of stent
crushing due to repeated extrinsic compression, we believe
balloon-expanded stents should be avoided unless one is
confident about a purely atherosclerotic etiology for the
stenosis. Self-expanding Nitinol stents are probably a more
appropriate choice in this location given the metal’s shape
memory and ability to withstand repetitive compression
stresses.
Our experience also demonstrated no difference in
clinical outcome and patency rate between patients with
simple stenotic lesions and those with occlusions or other
complex vascular lesions (such as long-segment stenoses,
irregular stenoses, and heavily calcified stenoses). Our series
included three patients with total occlusion of the SMA in
whom recanalization was attempted and was successful in
all three. In our opinion, the decision to treat an occlusion
should be based on necessity (for example, the presence of
occlusion in both SMA and CA). Moreover, we would only
attempt recanalization of an occluded mesenteric vessel
when the lateral aortogram shows a clear stump marking
the exact location of the occluded vessel.
Contraindications to endovascular revascularization in
mesenteric ischemia include suspected acute bowel ische-
mia with evolving bowel necrosis, a known or highly sus-
pected extrinsic compression as the underlying cause of the
stenosis, or the presence of extensive or diffuse disease or
stenosis involving the origin of major secondary branches,
that could be better addressed by open reconstruction.
Although the numbers were too small to allow a mean-
ingful analysis of significance, a poor clinical outcome ap-
peared to be related to instances of single-vessel disease that
were of only moderate severity (60%). Conceivably, a
normal duplex evaluation can further serve to assess the
clinical relevance of a single-vessel stenosis. The presence of
CA stenosis poses an inherently higher risk for immediate
failure due to recoil, as well as for delayed failures due to
metallic fatigue or dislodgement due to repetitive compres-
sion by the median arcuate ligament. This condition should
be suspected in the younger patient without evidence of
generalized atherosclerosis. When suspected, dynamic an-
giograms of the aorta in the lateral projection should be
performed in both inspiration and expiration before com-
mitting the patient to stenting.
Our results support the versatility of stenting to man-
age a variety of conditions in the mesenteric circulation
other than chronic mesenteric ischemia, including liver
transplant graft malfunction and as an adjunct preoperative
procedure in patients undergoing open repair for complex
juxtamesenteric AAA. Stenting could also be used as a
bailout modality in patients with renal bypasses based on
the mesenteric circulation in the presence of proximal
mesenteric vessel stenosis.
Although few would argue about the value of endovas-
cular therapy in poor operative risk patients, the use of
endovascular therapy in patients who are good operative
candidates has been more debatable. Prior studies have
compared open surgery with percutaneous angioplasty and
stenting in the management of chronic mesenteric ische-
mia, with some concluding that surgical therapy should be
preferentially offered to patients deemed fit for open revas-
cularization.3,4 The cumulative 5-year symptom-free sur-
vival for patients who undergo surgical treatment is re-
ported to be 70% to 88%.21,22 However, postoperative
morbidity can occur in up 54% of patients, and the periop-
erative mortality rates have been reported as high as
17%.23-25 Although follow-up in our series is limited, our
results as well as the results from other recent series17,18
suggest that the clinical efficacy and low complication rates
of visceral arterial stenting, by means of modern devices and
low-profile delivery systems, compare well with the known
morbidity and mortality of open surgical management of
occlusive mesenteric disease,21,22 and support the selective
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use of a primary endovascular approach. Recurrent disease
after stenting can usually be successfully managed by endo-
vascular means, and open surgery could be readily offered
for immediate or delayed failures not amenable to endovas-
cular treatment.
Although our initial results appear promising, they
represent a limited single institution experience with rather
short follow-up. Larger studies comparing stenting with
open surgery for occlusive mesenteric arterial disease are
needed to further define the role and indications of these
modalities.
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